Platform 02 · Biotech
Five steps become one
Purification is 50% to 80% of the production cost of a therapeutic protein. Not the fermentation, not the raw material: the purification. The Aybar Protocol collapses that sequence into a single chromatography step, on the equipment producers already own.
The comparison
Against hydroxylapatite chromatography, on the same enzyme
The reference figures below come from the purification of HGPRT’ase, the enzyme the protocol was developed and tested on. It has since been applied to several others, and is applicable in principle to any polypeptide or protein complex with ionic functional groups.
| Feature | Aybar Protocol | Hydroxylapatite |
|---|---|---|
| Stages | 1 step | 5 steps |
| Purification in this step | 23 fold | 5 fold |
| Time for 60 lb of yeast | 4–6 days | 6 months |
| Dilution in the effluent | 3–5 fold | 50 fold |
| Elution buffer volume | 1–3× void volume | 30× void volume |
| Column regeneration | 3 hours / 250 ml | Several days / 250 ml |
| Affinity column lifetime | Multiple cycles | 3 cycles |
Why it compounds
The saving is not in one line item
Older methods carry a specific set of drawbacks: heavy buffer consumption, low flow rates, loss of protein activity during the process, heavy dilution of the extract, difficult or impossible column regeneration, and a low purification fold that leaves debris polypeptides behind.
That last one is the expensive one, and it is the one nobody budgets for. Debris carried into the affinity chromatography step shortens the life of the affinity column, which is the most expensive consumable in the sequence. Purifying harder early makes the costly step last longer.
No capital expenditure
Adoption requires a fast protein liquid chromatography instrument, or any system with programmable injection, programmable buffer gradient, a pumping system, and preparatory columns packed with a suitable ion exchange resin. If a producer is purifying protein today, they already have this. No new machinery, no new facility, no capital line item.
Applications
Where purification cost decides the business case
Functional food ingredients
Collagen, soy and pea protein streams where yield and clean-label processing determine margin.
Nutraceutical extraction
Enzymes and immune peptides that are currently uneconomic to purify at scale.
Biotech and therapeutic proteins
Interferons, immunoglobulins and monoclonal antibodies, where purification dominates cost of goods outright.
Plant-based and alternative proteins
Emerging protein sources whose commercial viability depends on extraction economics rather than on raw material supply.
Commercial model
Paid out of the savings
Licensing priced on production volume, purification-as-a-service for producers who would rather not run it in house, and joint ventures with ingredient firms. Aybar Ecotechnologies retains a shareholding in the commercialization entity.
An offer that makes the claim testable. We will implement the procedure on one of your protein products at no cost to you, provided you supply the starting material and the facility. If the numbers on this page do not reproduce on your material, you have lost nothing.
Licensing & partnerships
Work with us on what comes next
Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.